Pulse Biosciences Reports Strong Clinical Data, FDA Approval for Pivotal AF Study, and Q4/FY25 Financials

summarizeSummary

Pulse Biosciences announced compelling clinical data for its nPulse Cardiac Catheter and FDA approval for a pivotal AF ablation study, alongside increased net losses and a declining cash balance for Q4 and full year 2025.

check_boxKey Events

• Compelling Clinical Data

  Reported 96% procedural success at one year for its nPulse Cardiac Catheter System in a feasibility study for atrial fibrillation ablation.

• FDA Pivotal Study Approval

  Received FDA approval to initiate a pivotal IDE study for the treatment of paroxysmal atrial fibrillation with its nPulse Cardiac Catheter System.

• Increased Net Loss

  Full year 2025 GAAP net loss widened to $72.8 million, compared to $53.6 million in the prior year.

• Declining Cash Balance

  Cash and cash equivalents stood at $80.7 million as of December 31, 2025, down from $118.0 million a year earlier, reflecting significant cash usage.

auto_awesomeAnalysis

Pulse Biosciences announced significant progress in clinical development, including compelling one-year procedural success rates for its nPulse Cardiac Catheter and FDA approval to commence a pivotal IDE study for atrial fibrillation. These are crucial milestones for advancing its proprietary technology towards commercialization. However, the financial results indicate a widening net loss and a substantial cash burn, reducing the cash runway. The concurrent at-the-market offering (as disclosed in a separate filing) suggests the company is proactively seeking to bolster its capital position to fund ongoing clinical trials and operations. Investors should weigh the strong clinical and regulatory advancements against the increasing financial needs.